Introduction: A large number of antiepileptic drugs (AEDs) are available today, but they may not be satisfactory regarding clinical effi cacy, tolerance, toxicity or pharmacokinetic properties. The purpose of this review is to focus upon the rationale behind the chemical modifi cations of several recently marketed AEDs or drugs in development and to categorize them according to the main purposes for the improvements: better effi cacy or tolerability accompanied by improved pharmacokinetic properties.
Introduction
A variety of antiepileptic drugs (AEDs) are available today, but still there is a need for new drugs, since the existing ones are not satisfactory regarding clinical effi cacy, tolerance, toxicity or pharmacokinetic properties. A new generation of the existing AEDs is in development, undergoing preclinical and clinical trials. These compounds have to be more potent, safer, and possess favorable pharmacokinetics to become a successful second-generation of AEDs (Bialer, 2006) .
It is important to emphasize that AEDs consist of a heterogenous group of drugs with various chemical properties, such as lipophilicity, ionization, and chirality. They have different chemical structures, and they may affect different target proteins (receptors, enzymes, transporters or voltage-gated ion channels). The seizure types are different in their origin, and patients suffering from epilepsy consist of a heterogenous group, phenotypically and genotypically different.
Both established and new AEDs are in clinical use or undergoing clinical trials in several psychiatric and neurological disorders other than epilepsy. These include migraine, neuropathic pain, bipolar disorder, mania, schizophrenia, anxiety, tremor, and still other conditions are under investigation (for review, see Rogawski and Löscher, 2004a; Spina and Perugi, 2004; Stefan and Feuerstein, 2007; Johannessen Landmark, 2007a) . The action of AEDs at the molecular level is incompletely understood, and most AEDs probably have more than one mechanism of action, each of which may contribute to the therapeutic effi cacy to a variable extent depending on the actual condition (Perucca, 2004; Johannessen Landmark, 2007a) . It is therefore diffi cult to divide the drugs into specifi c categories regarding their mechanisms of action and clinical effi cacy.
The purpose of the present review is to focus upon the rationale behind the chemical modifi cations of several recently marketed AEDs or drugs in development and to categorize them according to the main purposes for the improvements; namely better effi cacy or tolerability. These modifi cations are often also accompanied by improved pharmacokinetic properties.
Material and Methods
This review is based upon recent publications and PubMed searches on AEDs. The marketed AEDs included are carbamazepine, felbamate and fl uorofelbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, topiramate, and valproate. AEDs in development included brivaracetam, eslicarbazepine (BIA 2-093), ELB139, JZP-4, NS1209, carisbamate (RWJ 33369), talampanel, XP13512, and valproic acid derivatives (propylisopropyl acetamide (PID), 2,2,3,3-tetramethylcyclopropanecarbonylurea (TMCU), N-methyl-2,2,3,3-tetramethylcyclopropylamide (MTMCD), valnoctamide and valrocemide). The older AED phenytoin with its derivative fosphenytoin was not included, since this derivative has existed for almost ten years and the clinical use is limited to injections used in the treatment of status epilepticus.
Search terms used were the AEDs mentioned above, anticonvulsant, epilepsy, mechanism of action, effi cacy, tolerability, and pharmacokinetic properties, and combinations of these terms.
Relevant peer-reviewed articles in recognized, creditable international journals in English, from the earliest relevant data, 1983-2007, were included in the review. Primary sources were preferred, but review articles of specifi c importance were also included. Abstracts, unpublished or nonEnglish material, and papers of limited relevance or out-of-date results or choice of methods were excluded.
Strategies for Modifi cations and Monitoring of AEDs
Most AEDs have several mechanisms of action, and focus has been on designing new AEDs with specifi c mechanisms of action, or more selective effects on known target molecules for pharmacodynamic effects (Fig. 1) . The major improvements of the new derivatives are listed in Table 1 . Chemical modifi cations resulting in a better pharmacokinetic profi le have been emphasized for improving AEDs, resulting in better tolerability and effi cacy (Fig. 2) .
Basic pharmacokinetic parameters are the factors in the body that affects the drug from the time it is taken, including absorption, distribution, metabolism and excretion (Fig. 2) . A drug is absorbed to the systemic circulation, where it may be bound to plasma proteins or distributed throughout body tissues (fat or fl uid). From the systemic circulation the free fraction (which may be neutral or ionized) of the drug is transported to its site of action to exert its pharmacodynamic effect. The drug is undergoing elimination via biotransformation through metabolic pathways and elimination (often through liver, kidneys and faeces). Other parameters derived from these basic processes are e.g. bioavailability and half-life, which affect the effi cacy of the drug, to which extent it reaches the site of action and how long it remains in the systemic circulation. A prolonged half-life of a drug or changed distribution in various body tissues may affect the effi cacy of the drug. Therapeutic drug monitoring (TDM) is a useful tool also in the treatment of patients using older as well as newer AEDs (Johannessen and Tomson, 2002; Monitoring of AEDs gives the opportunity to observe pharmacokinetic and pharmacodynamic interactions, to avoid side effects and toxic levels and active metabolites in the blood (Fig. 2) .
In the following, each of the parent drugs will be briefl y described, regarding pharmacological characteristics, including mechanism of action and clinical use and limitations. Chemical characteristics and modifi cations will then be described and discussed.
Improved Tolerability of New AEDs
The tolerability of AEDs has often been improved by modifi cations of pharmacokinetic properties to reduce potential toxic metabolic pathways or teratogenic effects, as for valproate, carbamazepine, and felbamate (Fig. 1) . Valproic acid or valproate, its corresponding base which most often is used in drug formulation, is a broad spectrum AED. It has been investigated through the past four decades with demonstrated effects in a variety of elecrophysiological, neurochemical, seizure and animal models, and several mechanisms of action have been proposed. Attention has been drawn to effects on enhancement of GABAergic neurotransmission, where valproate affects several enzymes related to GABA synthesis and degradation (Löscher, 2002ab; Johannessen and Johannessen, 2003; Johannessen Landmark, 2007b) . The effect of valproate on voltage-gated sodium channels, in addition to potassium and calcium channels, is no longer regarded as an important clinically relevant mechanism of action (Löscher, 2002ab; Johannessen et al. 2001; Johannessen and Johannessen, 2003) .
In addition, valproate is involved in modulation of intracellular signalling pathways. Effects on these intracellular proteins are regarded as important for the understanding of the pathophysiology of bipolar disorder as well as the effi cacy of valproate in bipolar disorder (Rogawski and Löscher, 2004ab; Anmann and Grünze, 2005; Johannessen Landmark, 2007ab) . Intracellular targets include modulation of inositol metabolism, kinases as ERK and MARCK, glycogen synthase-3, protein kinase C, and early inducible genes (Göttlicher et al. 2001; Phiel et al. 2001; Löscher, 2002ab; Johannessen and Johannessen, 2003; Harwood and Agam, 2003; Ju and Greenberg, 2003; Brunello and Tascedda, 2003; Anmann and Grünze, 2005) . Altered expression of a number of different genes expressed following valproate treatment in mice, indicates that valproate regulates a large number of different functional pathways in the brain (Chetcuti et al. 2005) .
Clinical use
Valproate is widely used in a number of neurological and psychiatric disorders today. It is extensively used in epilepsy and is effective in all seizure types, in addition to neuropathic pain, migraine, and bipolar disorder (Rogawski and Löshcer, 2004a; Spina and Perugi, 2004; Johannessen Landmark, 2007a; A drug is absorbed to the systemic circulation, where the drug may be bound to plasma proteins or distributed throughout body tissues (fat or fl uid). It is only the free fraction of the drug in plasma that can exert an effect. From the systemic circulation the drug is transported to its site of action to exert its pharmacodynamic effect. The drug is undergoing elimination via biotransformation through metabolic pathways and elimination (often through liver, kidneys and faeces). The block arrows point to modifi cations in effi cacy by pharmacodynamic (mechanism of action) factors, and tolerability by modifi cations of pharmacokinetic parameters. (Dou et al. 2003; Eyal et al. 2005; Ichikawa et al. 2005; Yeow et al. 2006) . Since valproate has several proposed mechanisms of action, it is regarded as a broadspectrum drug with a wide therapeutic potential.
Perspectives in Medicinal
A fatale adverse effect of valproate is hepatotoxicity, its toxic metabolite being 4-ene valproate (Bailie, 1992) . Children less than 2 years old receiving Valproate in polytherapy and suffering from metabolic genetic disorders appear to be at highest risk for developing fatal hepatic dysfunction (1/600) (Bryant and Dreifuss, 1996) . Another restriction in the clinical use of valproate is the risk of teratogenicity. The incidence of congenital malformations in the offspring of mothers treated with valproate during pregnancy is 3 to 4 times higher than in offspring not exposed to valproate (Kaneko et al. 1999; Tomson et al. 2004; Perucca, 2005; Aldenkamp et al. 2006) .
Valproic acid analogues
A number of analogues have been investigated, and several of them have been designed as stable amide derivatives of valproic acid with no acidic function or minimal conversion to the acid (Bialer and Yagen, 2007) . Three strategies have been implemented in this attempt, the development of aliphatic amide analogues, cyclic derivatives, and amino acid conjugates, (Bialer, 2006; Bialer and Yagen, 2007) .
Some of the main derivatives will be briefl y presented including valrocemide (valproyl glycinamide), the tetramethylcyclopropyl analogue (TMCU) and isovaleramide (NPS 1776) (Isoherränen, 2001ab; Bialer et al. 2006; Sobol et al. 2006) (Fig. 3) . The valproic acid amide derivatives, valnoctamide, di-isopropylacetamide, and N-methyl-2,2,3,3-tetramethyl-cyclopropylamide (MTMCD) show more potent antiallodynic effects than valproic acid and exert minimal motor and sedative side effects at analgesic doses in a rat model of neuropathic pain and may consequently, become new drugs for the treatment of neuropathic pain (Winkler et al. 2005ab ). Investigations of the clinically relevant mechanisms of these second-generation substances are still ongoing. Valrocemide is undergoing phase II in clinical development (Bialer et al. 2006 ).
Chemical characteristics and modifi cations of valproic acid and its derivatives
Valproic acid (di-n-propyl acetic acid) or valproate, its corresponding base, and its simple structure of a short, branched fatty acid differs to a great extent from the substituted heterocyclic ring structures characterizing other older AEDs. Some of its derivatives are illustrated for comparison with the simple structure of the parent drug (Fig. 3) .
Aliphatic amide analogues and amino acid conjugates
The amide derivatives are more potent than valproic acid and their corresponding acids, and a series of structure-pharmacokinetic-pharmacodynamic relationships have been studied (Winkler, 2005 ab; Sobol et al. 2006; Bialer, 2006) .
In the simple structure of PID, the molecule is an acetamide, but the propyl isopropyl skeleton is present, resulting in one chiral center. It is the corresponding amide of valproic acid. In valrocemide, a glycinamide is attached to the carboxylic acid end of the molecule. In valnoctamide the carboxylic acid in vaplroic acid is replaced here by an amide like in PID, and one methyl group is reorganized to achieve two chiral centra. Racemic valnoctamide and the stereoisomers (2R,3S)-and (2S,3S) valnoctamide (with the best brain penetration) were demonstrated to be effective anticonvulsants in animal models of partial seizures and were more potent than valproic acid (Isoherrränen et al. 2003) . It seems reasonable that only one pair of the racemate is pharmacologically active, since biological complexing usually is stereoselective.
Cyclic derivatives
N-methyl-2,2,3,3-tetramethylcyclopropylamide MTMCD (MTMCD) is a cyclopropylamide with four methyl groups, and several other cyclic derivatives have been developed, as TMCU (Bialer, 2006; Sobol et al. 2006) . TMCU is similar to MTMCD but has an amide attached. These cyclic analogues possess two quanternary carbons in the β-position and cannot be biotransformed into the minor metabolites of valproic acid, 4-ene-VPA and 2,4-diene-VPA with a terminal double bond, which is presumed to be the source of hepatotoxicity (Konig et al. 1999; White et al. 2002; Sobol et al. 2005 ).
Modifi cations of carbamazepine Parent drug: Carbamazepine Proposed mechanism of action
The main action of carbamazepine is mediated through inhibition of voltage-activated sodium channels and consequently, inhibition of action potentials and excitatory neurotransmission. High frequency, repetitive neuronal firing is therefore limited (Kuo, 1998; Kuo et al. 2004) . The inhibitory potency is strongly use-dependent and accumulates with prolonged activation (Rogawski and Löscher, 2004b) . This is a classic mechanism of action for AEDs that is also shared by e.g. the older drug phenytoin, and several other AEDs as one of more mechanisms of action. In addition, as for valproate modulation of intracellular signalling pathways has been shown to be important for understanding of the pathophysiological background for bipolar disorder (Rogawski and Löscher, 2004a; Anmann and Grünze, 2005) .
Oxcarbazepine
Oxcarbazepine differs from carbamazepine as the drug inhibits several types of voltage-gated calcium channels (Ahmad et al. 2005) . Also for oxcarbazepine, modulation of intracellular signalling pathways is important for the pathophysiological background for bipolar disorder (Rogawski and Löscher, 2004a; Anmann and Grünze, 2005) . Oxcarbazepine is a non-toxic derivative of carbamazepine with a reduced drug interaction potential (Bialer et al. 2004; Schmidt and Elger, 2004) .
Clinical use of carbamazepine and oxcarbazepine
Oxcarbazepine has been available in Europe for many years but only recently in the US. Carbamazepine and oxcarbazepine are widely used in several neurological and psychiatric disorders. Carbamazepine is regarded as a fi rst-line drug in epilepsy, and it is also frequently used in neuropathic pain and bipolar disorder (Rogawski and Löscher, 2004a; Spina and Perugi, 2004; Johannessen Landmark, 2007a; Anmann et al. 2007 ). Both drugs are broadspectrum drugs, based on their mechanisms of action and wide clinical use. The goal for developing the derivatives of carbamazepine has been to avoid the potentially toxic epoxide-metabolite skin rash and less susceptibility to pharmacokinetic interactions, as it does not undergo inducible cytochrome CYP3A4-mediated oxidative metabolism in the liver (Bialer, 2006) .
Eslicarbazepine (BIA 2-093)
The carbamazepine analogue eslicarbazepine acetate, BIA 2-093, (S9-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide was designed for improved effi cacy and safety . BIA 2-093 is a derivative of carbamazepine and oxcarbamazepine, and is a prodrug for the main active metabolite (S)-licarbazepine ). The compound is currently undergoing clinical phase III trials in epilepsy and phase II trials in bipolar disorder ).
Chemical characteristics and modifi cations of carbamazepine and its derivatives
Carbamazepine is a dibenzoazepine, a carbamate, its main metabolite being the 10,11-epoxide. This unstable epoxide is not toxic, in contrast to other epoxides that are formed after enzymatic degradation in the liver (Fig. 4) . In the structure of its derivative oxcarbazepine, there is addition of a ketone group on the N-containing cyclic structure. Oxcarbazepine is a prodrug for the main active metabolite, monohydroxy derivative (MHD), 10-hydroxy-10,11-dihydro carbazepine, that can be measured in the blood for therapeutic drug monitoring purposes (Johannessen and Tomson, 2006) . BIA 2-093 is a dibenzazepine derivative of carbamazepine and oxcarbamazepine, and is a prodrug for the main active metabolite (S)-licarbazepine, which is one of the enantiomers of MHD (Fig. 4) .
Modifi cations of felbamate Parent drug: Felbamate Proposed mechanisms of action
Felbamate is regarded as a broad-spectrum AED with several proposed mechanisms of action, including antagonism at the glutamatergic NMDA receptor at the NR2 subunit, in clinically relevant concentrations (Kuo et al. 2004 ). Other mechanisms of action include inhibition of voltage-gated sodium and calcium channels (Rogawski and Löscher, 2004b) .
Clinical use
After serious adverse events including aplastic anemia and liver failure caused by production of a reactive metabolite of felbamate in a limited number of the patient population, the use of the drug was thoroughly considered. The clinical use of felbamate is now limited and is only used in some forms of refractory epilepsy and Lennox Gastaut syndrome in children (Perucca, 2004) .
Fluorofelbamate
A non-toxic analogue, fl uorofelbamate, 2-phenyl-2-fl uoro-1,3-propanediol dicarbamate, was developed due to the serious adverse effects of felbamate. Its mechanisms of action cannot be completely explained by either interactions at glutamate receptor sites or sodium channels (Wallis et al. 2000) . It protects against ischemia and hypoxia in vitro and in vivo (Wallis et al. 2000) . Fluorofelbamate is undergoing preclinical trials, and has shown to be effective in a rat model of status epilepticus (Mazarati et al. 2002; ). Preclinical fi ndings suggest that fl uorofelbamate is not metabolized to the known reactive metabolite of felbamate, where possibly the upper amide group is cleaved off the molecule to give felbamate 2-phenylpropanal (ATPAL) (Parker et al. 2005) . The fl uor atom will protect the amide groups by its inductive effect, as the size of the ion radius of fl uor compared to hydrogen is similar.
Carisbamate (RWJ-333369)
Another derivative of felbamate is carisbamate, (S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol. Carisbamate (RWJ-333369) is undergoing phase II and III clinical trials and seems to be well tolerated (Bialer, 2006; . The compound has been tested in several preclinical models and has a favorable profi le in epilepsy models, such as corneal kindling, hippocampus kindling, a genetic absence epilepsy rat model (GAERS) and chemically induced seizures ).
Chemical characteristics and modifi cations of felbamate and its derivatives
Felbamate is a symmetrical molecule with a benzene ring structure attached to a central carbon atom with a diether binding to two amide groups (Fig. 5) . In fl uorofelbamate one fl uor atom is attached to the central carbon atom to prevent the formation of the reactive toxic metabolite of felbamamate, ATPAL (Bialer, 2006) (Fig. 5) . In carisbamate a chloride atom is attached to the aromatic ring, and an amide containing side chain has been included, resulting in a chiral centrer (Fig. 5) .
Modifi cations of lamotrigine Parent drug: Lamotrigine Proposed mechanisms of action
The principal mechanism of action of lamotrigine appears to involve inhibition of voltage-activated sodium channels, resulting in increased inhibition of action potential firing activity by a usedependent mechanism (Xie et al. 1995; Kuo, 1998) . Lamotrigine also inhibits high-voltageactivated calcium channels that are located presynaptically, including the N-and P-type, and consequently, inhibits neurotransmitter release, such as glutamate (Xie and Hagan, 1998) . Another novel mechanism of action is that lamotrigine selectively decreases action potential fi ring by an increase in the dendritic hyperpolarization-activated cation current (I h ), since the dendrites have different electrical properties from the soma in pyramidal cells (Poolos et al. 2002) . This target would be of importance in epileptogenesis (Poolos et al. 2002) .
Clinical use
Lamotrigine is extensively used in epilepsy, neuropathic pain, and bipolar disorder, based on its inhibitory effect on excitatory neurotransmission (Rogawski and Löscher, 2004ab; Spina and Perugi, 2004; Eisenberg et al. 2005; Nierneberg et al. 2006) . In addition, lamotrigine may be benefi cial in the treatment of other disorders, such as migraine or schizophrenia (Rogawski and Löscher, 2004a; Lampl et al. 2005; Muzina et al. 2005; Premkumar and Pick, 2006; Johannessen Landmark, 2007a; Anmann et al. 2007 ).
JZP-4
JZP-4, 3-(2,5-trichloro-phenyl)-pyrazine-2,6-diamine, is a derivative of lamotrigine. It is a novel potent sodium and calcium channel inhibitor, which displays broad-spectrum anticonvulsant activity ). The substance has demonstrated a favorable profi le in toxicology and pharmacokinetic studies so far ).
Chemical characteristics and modifi cations of lamotrigine and its derivative
Lamotrigine is a 1,2,4-triazine, with two chloride atoms attached (Fig. 6) . In JZP-4, one nitrogen atom has been removed from the cyclic structure, and another chloride is attached to the aromatic ring (Fig. 6 ). The two drugs are different in structure since cyclic structures with two nitrogen atoms are commonly occurring in biological molecules, while three nitrogens are not common. Both molecules are neutral in physiological pH. The modifi cations in JZP-4 may affect the metabolic route of elimination for lamotrigine.
Comments
In this section, chemical modifi cations of AEDs, developed to reduce toxic effects, the risks of specifi c adverse effects and interaction potential have been described. The new derivatives have improved tolerability and pharmacokinetic properties. The main AEDs used today in epilepsy and other disorders as bipolar disorder and neuropathic pain are valproate, carbamazepine and lamotrigine. These drugs have several new effective and safe derivatives that hopefully will be clinically useful within the coming years.
Improved Effi cacy of New AEDs
One way to improve effi cacy of AEDs is by designing a better pharmacodynamic profi les with more specifi c mechanisms of action based on new pathophysiological fi ndings. New AEDs in development will hopefully result in better chemical and pharmacological characteristics than the existing substances. The proposed mechanisms of action of these drugs are illustrated in the synapses by the main inhibitory neurotransmitter GABA and the main excitatory neurotransmitter glutamate with their main targets for pharmacological action (Fig. 1) . The main pharmacodynamic mechanisms responsible for the clinical effi cacy of AEDs include increased GABAergic or decreased glutamatergic neurotransmission, inhibition of voltage-gated ion channels or modifi cations of intracellular signalling pathways (Rogawski and Löscher, 2004b; Johannessen Landmark, 2007b) . A common result of pharmacological intervention with these drugs is a decrease in neuronal excitability. The main modifi cations of AEDs and their main achievements are listed in Table 1 . Most AEDs bind to target macromolecules where the neurotransmitters GABA or glutamate bind, such as receptors and transporters, or to voltage-gated ion channels. Structurally, some of the AEDs may have structural similarities with these amino acid neurotransmitters (Fig. 7) , such as gabapentin. Most AEDs have several target molecules in common with the endogenous neurotransmitters (receptors, enzymes, reuptake proteins). In addition, pregabalin and gabapentin are structurally related to GABA.
Modifi cations of levetiracetam Parent drug: Levetiracetam Proposed mechanisms of action
Levetiracetam is a unique broad-spectrum AED that did not show any effect in the commonly used epilepsy models, but it was effective in a genetic absence epilepsy model (GAERS) (Bialer et al. 2004 , Stratton et al. 2003 . A novel binding site for levetiracetam has been identifi ed as the synaptic vesicle protein 2A (SV2A) in the presynaptic neuron (Lynch et al. 2004) . It is still unclear how levetiracetam and SV2A interact, but it has been proposed that it is essential for exocytosis of neurotransmitter from the presynaptic neuron into the synaptic cleft and may prevent exocytosis of glutamate, since there is a correlation between binding affi nity and potency in suppressing tonic seizures in audiogenic sensitive mice (Lynch et al. 2004 ). In addition, for other AEDs like gabapentin and pregabalin that target voltage-activated sodium and calcium channels (including α2δ), inhibition of glutamate release is likely to be a critical downstream action for seizure protection (Rogawski and Löscher, 2004a; Rogawski, 2006) . Levetiracetam may also infl uence GABAergic activity by increasing chloride currents and consequently enhancement of inhibitory GABAergic neurotransmission, and glycin could also be affected (Poulain et al. 2002; Rigo et al. 2002) . Inhibition of glycin release could indirectly reduce the activity of the NMDA receptor of glutamate, since this receptor is dependant on the binding of both glutamate and glycin to open the ion channel. Recently, enhancement of release of inhibitory neurotransmitters has also been proposed (Stefan and Feuerstein, 2007) . It seems more likely, however, that exocytosis is inhibited rather than enhanced when levetiracetam possibly interacts with the docking process of exocytosis of neurotransmitter from the presynaptic neuron.
Clinical use
Levetiracetam is used in epilepsy and neuropathic pain and is under investigation for further clinical use, as in essential tremor (Rogawski and Löscher, 2004a; Handforth and Martin, 2004; Bushara et al. 2005; Johannessen Landmark, 2007a) . It is extensively used in several seizure types in many patients with refractory epilepsy Stefan and Feuerstein, 2007; Johannessen Landmark et al. 2007 ).
Brivaracetam and seletracetam
Two promising novel drug derivatives of levetiracetam are in developement, brivaracetam (ucb 34714) and seletracetam (ucb 44212). They optimize the unique mechanism of action and may further improve medical management of epilepsy (Klitgaard, 2005; Von Rosenstiel et al. 2007; Bennett et al. 2007 ). Brivaracetam could possibly have a broader therapeutic spectrum than its parent drug since it also inhibits voltage gated sodium channels (Rogawski, 2006) . These derivatives have been tested in phase I studies ). Comparable studies of the two drugs are, however, lacking, regarding mechanisms of action and effi cacy in preclinical models.
Chemical characteristics and modifi cations of levetiracetam and its derivatives
Levetiracetam is a 5-oxopyrolidine with a lactam ring structure with one chiral centre, and the S-enantiomer is present (Fig. 8) . Seletracetam and brivaracetam are derivatives of levetiracetam that are substituted at the 4-position in the 2-pyrrolidinone ring (Fig. 8) . The chemical difference in the two new compounds is the addition of a propyl group in brivaracetam. In seletracetam, a vinyl group including two fl uor atoms is added in the same position as a steric hinder to avoid chemical interactions. All three molecules are neutral in physiological pH. The two derivatives have one additional chiral centre, giving two stereoisomers each. Stereoselectivity in the binding of these molecules seems likely to occur. These modifications result in a potentiated binding to the SV2A protein, up to 10-fold compared to levetiracetam in several models for epilepsy, like cornea kindling and the GAERS absence seizure model (Crowder et al. 1999 , Lynch et al. 2004 , Bennett et al. 2007 , Von Rosenstiel et al. 2007 . Gabapentin was synthesized as a GABAergic substance and is structurally related to GABA, but does not interact with GABA receptors or its uptake or degradation processes (Sills, 2006) . Gabapentin and pregabalin are ligands of α2δ (1 and 2) voltageactivated calcium channel subunits that are overexpressed in sensory neurons after nerve injury (Marais et al. 2001; Bian et al. 2006 ). Inhibition of voltage-gated calcium channels in the presynaptic neuron will inhibit glutamate release at excitatory synapses and thereby a decrease in excitatory neurotransmission (Rogawski and Löscher, 2004a) .
Pregabalin
A structurally related compound to gabapentin is pregabalin, (S)-3-aminomethyl-5-methylhexanoic acid. Pregabalin has the same binding-affi nity as gabapentin to the α2δ (1 and 2) subunits, which strongly implicates that these subunits are important for the pharmacological effect (Marais et al. 2001; Bian et al. 2006 ). The subunits are major binding proteins for pregabalin in neocortex, hippocampus, amygdala, and spinal cord, as demonstrated in genetically modified mice (Bian et al. 2006) . It remains to be determined, however, whether an interaction with high-voltage-activated calcium channels is suffi cient to account for the broad-spectrum activity of gabapentin and pregabalin (Sills, 2006) .
Clinical use of gabapentin and pregabalin
Gabapentin and pregabalin have recognized effi cacy in the treatment of both epilepsy and neuropathic pain, and to some extent in migraine, and they are both marketed in many countries (Landy et al. 2004; Sills, 2006) . The inhibition of voltagegated calcium channels is supposed to be involved in pain relief (Marais et al. 2001; Rogawski and Löshcer, 2004a, Sills, 2006; Bian et al. 2006) . Gabapentin has also demonstrated effi cacy in essential tremor, which is associated with a defi ciency in GABAergic function (Kralic et al. 2005; Jankovic and Noebels, 2005; Rodrigues et al. 2005 ).
XP13512
A new derivative is in development as a prodrug of gabapentin, XP13512, [( + /−)-1-([(alpha-isobu tanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], avoiding capacity-limited absorption from the intestine following oral administration (Cundy et al. 2004; Bialer, 2006) . It is going through phase II in clinical trials (Bialer, 2006) . Its potential clinical use will possibly be primarily epilepsy and neuropathic pain.
Chemical characteristics and modifi cations of gabapentin and its derivatives
The structures of gabapentin and pregabalin are derived from GABA, but they are one atom longer, with six instead of fi ve carbon or nitrogen atoms in a row. Both drugs are inactive at GABA receptors (Taylor et al. 2006) (Fig. 9) . Unlike GABA both drugs have bulky aliphatic chemical substitutions at the 3-position of GABA, which changes their pharmacological properties significantly in comparison to GABA (Taylor et al. 2006) . In gabapentin, there is an amino acid-like structure with a carboxylic acid ending and one amino group ending, attached to a cyclohexane (Fig. 9 ). In pregabalin, there is a central chiral atom in the 4-position, and the amino acid-like structure is kept. The cyclic hexane structure has been replaced with an aliphatic side chain. These aliphatic amines are positively charged at physiological pH. The gabapentin derivative XP13512 has got an addition of a diesther group to the amino ending of the molecule (Fig. 9 ).
Compounds related to topiramate
Parent drug: Topiramate
Proposed mechanisms of action
Topiramate is a pharmacologically rich neuroactive drug that has been demonstrated to possess many molecular activities, such as inhibition of voltagegated sodium channels, modulation of voltagegated potassium and calcium channels, modulation of GABA A and glutamate receptors, and carbonic anhydrase inhibition (Bialer et al. 2004; White, 2005) . Among its complex actions, topiramate is a selective antagonist at the glutamatergic kainate receptor, a potential and important target regarding minimizing the potential toxicity caused by prolonged glutamatergic activation by NMDA receptors (Kaminski et al. 2004; Muir, 2006) . It is rather remarkable that the unusual structure of topiramate may affect these distinct targets including receptors, ion channels and enzymes.
Clinical use
Topiramate is used in epilepsy, migraine and tremor (Silberstein et al. 2004; White, 2005; . Topiramate may have a potential for clinical use in treatment-resistant schizophrenia, even though the outcome was moderate in one clinical study (Tiihonen et al. 2005) . Furthermore, the drug has been tested in other neurological and psychiatric conditions, such as anxiety, bipolar disorder, and neuropathic pain (Van Ameringen et al. 2004; Bartolini et al. 2005; McIntyre et al. 2005; Johannessen Landmark, 2007a) . The following compounds are not structurally related to topiramate, but are compounds with a similar mechanism of action compared to some of the actions mediated by topiramate, e.g. antagonists to glutamatergic and GABAergic receptors. Efforts have been focused on improving the selectivity of potential AEDs to these receptors.
Talampanel
It has been diffi cult to develop antagonists to ionotropic glutamate receptors, both due to the high endogenous extracellular glutamate concentration and the possible side effects on cognition and memory. Talampanel is a selective non-competitive antagonist at the AMPA receptor (Rogawski, 2006; Solyom et al. 2002) . Talampanel has been suggested to be active in neuroprotection as well as in epilepsy (Bialer, 2006) . Two putative noncompetitive antagonist sites are known. These binding sites are linked to the cation channel of the AMPA receptor . Clinical trials of talampanel are ongoing in phase II ).
NS1209
NS1209 is a selective, competitive AMPA receptor antagonist (Rogawski, 2006; Solyom et al. 2002) . AMPA receptors are key mediators for seizure spread. Calcium permeability of AMPA receptors lacking the GluR2 subunit in the amygdala and hippocampus has been studied, and they could play a role in synaptic plasticity, epileptogenesis and excitotoxicity (Gryder et al. 2005) . These receptors are promising targets for further investigations. There is a recognized glutamate binding site on the AMPA receptor subunit, where competitive antagonists like NS1209 bind.
Chemical characteristics and modifi cations of topiramate and related compounds
The following structures are not very similar chemically but bind to a common target protein, the AMPA receptor. Topiramate is a tetrahydropyrane with one sulphonamide attached. Two acetal groups with two methyl groups each are attached to the molecule to protect the substituents (Fig. 10) . Talampanel is a diazepine derivative, the 3-acetylated, 3-4-dihydro analogue of GYKI 52466, which is the prototype of the 2,3-benzodiazepine class of AMPA receptor antagonists (Donevan and Rogawski, 1993) . NS1209 is an indole derivative included in a big heterocyclic structure with several attached groups, including one sulphonamide group (Fig. 10) The benzodiazepines bind to the benzodiazepine receptor within the benzodiazepine-GABA A receptor complex. Agonists at the GABA A receptor enhance the inhibitory GABAergic neurotransmission throughout the CNS. The various GABA A receptor subtypes are different in their specifi c regional and cellular localization, they consequently serve distinct neuronal circuits and functions. A deficit in the α 3 -subunit in GABA A receptors was linked to dopaminergic hyperfunction, which is considered to be a contributing factor to the development of schizophrenia, and agonists at these receptors would be of importance (Yee et al. 2005) .
Clinical use
Benzodiazepines are used worldwide as anxiolytics, sedatives and anticonvulsant drugs. The potential for development of tolerance, dependence and abuse, is, however, a limitation in their clinical use (Löscher and Schmidt, 2006) . The new derivatives may have a clinical potential in anxiety and epilepsy.
ELB139
Various selective partial benzodiazepine receptor agonists are being developed, including ELB139, [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-on], a positive allosteric modulator of α3-containing GABA A receptors (Langen et al. 2005) . In a recent study, ELB139 showed functional subtype specifi city to several GABA A receptor subtypes, and partial agonism at various subtypes, differently from diazepam (Rabe et al. 2007 ). Its main clinical use seems to be anxiety, although it may have a potential in epilepsy (Rogawski, 2006) .
Ganaxolone
Ganaxolone (3-α-hydroxy-3-β-methyl-5-α-pregnan-20-on) is the 3-β-methylated synthetic analogue of allopregnanolone (Fig. 11) . It is a neuroactive progesterone-analogue that acts as a positive modulator of GABA A receptors, since there is a specifi c binding site for these pregnanolones (Foster and Kemp, 2006) . It is a member of a novel class of neuroactive steroids called epalones, and it allosterically modulates the GABA A receptor complex via a unique recognition site (Bialer et al. 1999) . Ganaxolone has demonstrated effi cacy in preliminary clinical trials, in infantile spasms in children and as monotherapy in adults (Kerrigan et al. 2000; Laxer et al. 2000) . It is currently undergoing further development in infantile spasms, in women with catamenial epilepsy, and in adults with refractory partial-onset seizures (Nohria and Giller, 2007) . The potential for clinical use of ganaxolone seems to be rather limited based on the absence of recent publications of further investigations regarding this drug, possibly due to pharmacokinetic problems and limited absorption, and reformulation of the drug is ongoing (Bialer et al. 1999; Nohria and Giller, 2007) .
Chemical characteristics and modifi cations of benzodiazepines, neurosteroids and their derivatives GABA A -agonists Chemically, ELB-139 is related to the benzodiazepines, as both drugs consist of heterocyclic ring structures that possibly bind similarily to the GABA A receptor, although this new derivative is subtype selective.
Neurosteroids
Ganaxolone has a steroid skeleton very similar to progesterone, with a difference in the hydroxyl group instead of a keton and a double bond in the A-ring of the cholesterol skeleton (Fig. 11) . It lacks, however, hormonal activity (Bialer et al. 1999 ).
Comments
In this section important target molecules for AEDs have been discussed in relation to the different classes of AEDs. The molecules that have been focused upon include voltage gated sodium and calcium channels, proteins associated with exocytosis of neurotransmitters (SV2A), and receptor molecules for GABA (GABA A ) and glutamate (AMPA receptors). Further investigations with potential AEDs should be accompanied by pharmacogenetic studies to elucidate modifi cations in the target molecules of AEDs, which also may be altered in pathophysiological processes (as in anxiety with altered subunit expression of the GABA A receptors and neuropathic pain where an over-expression of the α2δ subunits of the voltagegated calcium channel is present).
Conclusions
Several AEDs of a new generation have been developed from the existing drugs. Develoment of new derivatives is important to achieve new drugs with improved pharmacokinetic and-dynamic properties, resulting in better tolerability and efficacy. The AEDs consist of a group of heterogenous chemical structures, unrelated to each other, but affecting the same target proteins. Important target molecules, which have been focused upon include voltage gated sodium and calcium channels, proteins associated with exocytosis of neurotransmitters, and receptor molecules for GABA and glutamate. New drugs will hopefully affect pathophysiological processes or altered target proteins more selectively than older drugs. Further effort should be put into more detailed structure-activity relationship studies including investigations regarding stereoselectivity. There will be a resistant need for improvement of effi cacy and tolerability of the existing drugs, as well as newly discovered substances with novel mechanisms of action may become of importance in future drug therapy in epilepsy in addition to other CNS disorders.
